Chiesi signs $1.9B deal to acquire KalVista and its approved drug
Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KALV} in cash to buy the ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · IT
- [CONFLICT] Hatay'da belediyenin kazısında kaya mezarı bulundu
- [CONFLICT] Fenerbahçe'den gönderilen Domenico Tedesco'ya İtalya'dan talip çıktı!
- [TECH] Italy's Pirelli buys 30% of Sweden's Univrses to boost AI tyre tech
- [CONFLICT] Hatay'da belediyenin kazısında insan kemikleri bulundu: Bölgeye giriş çıkışlar kapatıldı
- [CONFLICT] Italian convicted of adultery in Egypt amid custody battle
- [CONFLICT] Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion